AstraZeneca Plc (LON:AZN) today announced that the European Commission has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorisation..
AstraZeneca Plc (LON:AZN) today announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD)...
AstraZeneca Plc (LON:AZN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth..
AstraZeneca PLC (LON:AZN) and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency has granted orphan designation..
AstraZeneca PLC (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has..
AstraZeneca PLC (LON:AZN) has agreed to sell the commercial rights to Atacand and Atacand Plus in Europe to Cheplapharm Arzneimittel GmbH. Atacand is a prescription medicine for the treatment of..
AstraZeneca PLC (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after..
AstraZeneca and Merck & Co (LON:AZN), Inc., Kenilworth, N.J., US today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets. Women with BRCA-mutated..
AstraZeneca Plc (LONAZN) and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled, multi-centre..
AstraZeneca Plc (LON:AZN) has today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer..
